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Abstract: Antisynthetase syndrome (aSS) corresponds to an overlap-
ping inflammatory myopathy identified by various myositis-specific
autoantibodies (directed against tRNA-synthetases). Myocardial invol-
vement in this condition is poorly described.
From a registry of 352 aSS patients, 12 cases of myocarditis were
retrospectively identified on the basis of an unexplained increase in
troponin T/I levels associated with either suggestive cardiac magnetic
resonance imaging (MRI) findings, nonsignificant coronary artery
abnormalities or positive endomyocardial biopsy.
The prevalence of myocarditis in aSS is 3.4% and was not linked to
any autoantibody specificity: anti-Jo1 (n¼ 8), anti-PL7 (n¼ 3), and
anti-PL12 (n¼ 1). Myocarditis was a part of the first aSS manifestations
in 42% of the cases and was asymptomatic (n¼ 2) or revealed by an
acute (n¼ 4) or a subacute (n¼ 6) cardiac failure. It should be noted that
myocarditis was always associated with an active myositis. When
performed (n¼ 11), cardiac MRI revealed a late hypersignal in the
T1-images in 73% of the cases (n¼ 8). Half of the patients required
intensive care. Ten patients (83%) received dedicated cardiotropic
drugs. Steroids and at least 1 immunosuppressive drug were given in
all cases. After a median follow-up of 11 months (range 0–84) 9 (75%)
patients recovered whereas 3 (25%) developed a chronic cardiac
insufficiency. No patient died.
The prevalence of myocarditis in aSS is similar to that of otherilia, Jean-Luc Pel chulla,
d Baptiste Hervier
(Medicine 94(26):e798)
Abbreviations: aSS = antisynthetase syndrome, EB =
endomyocardial biopsy, MRI = magneic resonance imaging.
INTRODUCTION
A ntisynthetase syndrome (aSS) belongs to the category ofautoimmune inflammatory myopathies and is characterized
by the presence of various but mutually exclusive anti-tRNA-
synthetase autoantibodies. Its spectrum often includes myositis
with interstitial pneumonia, Raynaud’s phenomenon, inflam-
matory polyarthralgia/polyarthritis, and mechanic’s hands.1,2
Cardiac involvement in inflammatory myopathies is poly-
morphic and includes subclinical (electromyographic) changes
or different features like congestive heart failure,3,4 pulmonary
hypertension,5 pericarditis,6 and myocarditis. This latter mani-
festation seems to be particularly rare in aSS, with only a few
case reports published to date.7,8 Although potentially severe,
this condition could be underestimated.
Myocarditis can occur in contexts other than myopathies,
including infectious or inflammatory diseases or hypereosino-
philia.7,8 Diagnosing myocarditis remains difficult and the
clinical classification criteria are still a matter of debate. Based
on the WHO classification, myocarditis is an inflammatory
myocardial injury and is defined based on an endomyocardial
biopsy (EB) with specific histological and immunological
features.9–11 However, performing an EB is risky and is now
only rarely performed, especially when cardiac-magnetic reson-
ance imaging (MRI) is suggestive.9–13
Diagnosing myocarditis remains a challenge in patients
with an autoimmune disease, particularly with inflammatory
myopathies. This is because the clinical manifestations can
be subclinical, nonspecific, or concealed by other clinical
features, including pericarditis or lung involvement. It is
however crucial to diagnose myocarditis, due to the need for
specific treatments, and to avoid a potentially fatal early
evolution or the development of chronic heart failure at a
later stage.
We have conducted the largest retrospective series to date,
with the objective of describing myocarditis in the context of
aSS, specifying its prevalence and outcomes.
PATIENTS AND METHODS
The myocarditis cases occurring during aSS (n¼ 12) wered from the French national registry
ty centers, 2000–2014). Myocarditis
urrence of acute (<24 hours) or subacute
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(24–72 hours) cardiac symptoms associated with either
increased troponin I or T (which are highly specific for cardi-
omyocyte necrosis)14,15 and suggestive cardiac-MRI or EB
(patient # 10) and in the absence of any other significant cause
(including viral infection, coronaropathy, or valvulopathy). It
should be noted that 2 eligible patients who died before specific
morphological examination were not included, despite a com-
patible myocarditis diagnosis. Demographic data, clinical, bio-
logical and morphological findings, treatments, and outcomes
were retrospectively reviewed by CD,1 CD,2 and BH, using the
same form. The study was approved by local ethical commit-
tees, and patients were reported anonymously, in accordance
with French law.
RESULTS
Of the entire cohort, 12 patients (3.4%, woman/man
ratio¼ 3, median age 54, range 17–67) were identified as
meeting the classification criteria. Cardiovascular risk factors
were found in half of the cases (n¼ 6) but rarely significant.
Their distribution was smoking habit (n¼ 2), systemic hyper-
tension (n¼ 2), dyslipidemia (n¼ 2), obesity (n¼ 2), and mild
diabetes mellitus (n¼ 3), see Table 1.
Among the clinical features of aSS, myocarditis was one of
the first aSS manifestations in 42% (n¼ 5) of the cases. In the
other cases, myocarditis occurred during the follow-up period
(median 36 months, range 8–156). In only 3 (43%) of these
cases were the patients treated with immunosuppressive drugs
at the time of the myocarditis diagnosis. Myocarditis manifes-
tations included left and/or right ventricular dysfunction
(n¼ 10), which was often severe (leading to congestive heart
failure with New York heart association stage III: n¼ 9).
Intensive care was indeed required 6 times (50%). Chest pain
was reported 3 times (25%). These clinical features were acute
(n¼ 4) or subacute (n¼ 6). Two patients presented without any
symptom consistent with heart failure. Electrocardiography
showed sinusal tachycardia (n¼ 6), heart branch block
(n¼ 5), and/or atrial arrhythmias (n¼ 2). Repolarization defects
were also observed (n¼ 4, see Table 1).
Troponin I or T levels were significantly elevated in all of
the tested cases (19 times the normal range, 1.5–160), as was
creatine kinase (38 times the normal range, 2–190).
Transthoracic echocardiography revealed pericarditis in
6 cases (50%), with compression in 1 case. Left-ventricular
ejection fraction was decreased in 7 cases (median of 46%,
27–55) and normal in the remaining 5 cases. Two patients
had a significantly dilated ventricle but none was hypertrophic.
No significant valvulopathy was observed and pulmonary
hypertension was at least ‘‘possible,’’16 in 4 cases (33%).
Cardiac-MRI (n¼ 11) revealed a spontaneous T2 hyper-
signal in 3 cases (27%) and/or a T1-gadolinium late signal
suggestive of myocarditis in 7 cases (73%, see Figure 1) and no
T1-gadolinium early signal was observed. In the remaining
case, EB showed focal active and chronic inflammatory lesions
with both lymphocytes and neutrophils invading the myo-
cardium, consistent with the diagnosis of myocarditis. Coro-
narography (n¼ 7) and coro-CT-scan (n¼ 2) were normal or
did not show significant atheroma explaining the ventricular
lesions. Viral screening was negative (n¼ 11), with the excep-
tion of patient 7, who presented with a slightly positive cyto-
Dieval et almegalovirus blood replication (blood copy number by
polymerase chain reaction¼ 3.2 log). Causality was however
not confirmed in this case.
2 | www.md-journal.comAccording to these findings, and based on Sagar et al,10
myocarditis was ruled a definite myocarditis in 1 case with EB
(8%), a probable acute myocarditis in 6 cases (50%), and only a
possible subclinical acute myocarditis in the 5 remaining cases
(42%).
Aside from heart involvement, other clinical aSS features
observed at the time of aSS initial diagnosis or during the
follow-up period were similar to those commonly described in
larger aSS cohorts.1,2 These manifestations however included
active myositis in all cases, interstitial pneumonia in 83% of the
cases, and less commonly dermatologic and rheumatic mani-
festations (see Table 1). Of note, no patient presented with
erosive arthritis or aSS-rheumatoid arthritis overlapping syn-
drome. Various anti-tRNA-synthetase autoantibody specifici-
ties were found anti-Jo1 (n¼ 8), anti-PL7 (n¼ 3), and anti-
PL12 (n¼ 1). The prevalence of other associated autoanti-
bodies, including anti-Ro/SSA and anti-La/SSB, was similar
to what has been reported previously.2 All patients were antici-
trullinated peptide/protein antibody negative.
The treatments targeted both the heart and the immune
system. Cardiac treatment consisted of diuretic (n¼ 9), beta-
blockers (n¼ 6), angiotensin inhibitors (n¼ 4), antiarrhythmic
drugs (n¼ 2), and inotropic drugs (n¼ 2). Pericarditis drainage
was performed once. Immunosuppressive drugs initially
included steroids in all of the cases associated with intravenous
immunoglobulins (n¼ 4), intravenous cyclophosphamide
(n¼ 4), and anti-CD20 monoclonal antibodies (n¼ 3). Oral
immunosuppressive drugs were also administered, among
which mycophenolate mophetil or azathioprine were the most
common (n¼ 4 cases each, see Table 1). Of note, a second
therapeutic line was necessary in 3 cases (30%).
With a median follow-up of 11 months (0–84), 2 different
outcomes were observed. Eight patients (75%) presented with
normal heart examinations, despite a relapse of pericarditis in 1
case. However, 3 patients developed chronic heart failure, with
several relapsing episodes (n¼ 3). In these 3 cases, transthoracic
echocardiography showed altered left ventricular function, with
significant left ventricle dilation in 2 cases. No patient died.
Taken as a whole and consistent with Cooper et al,9 these
results suggest the following myocarditis distribution: an acute
myocardial infarction-like syndrome with normal coronary
arteries (n¼ 6, 50%), heart failure with normal-sized or dilated
Medicine  Volume 94, Number 26, July 2015left ventricle and hemodynamic compromise (n¼ 3, 25%), and
heart failure with dilated left ventricle, new ventricular arrhyth-
mia, and 3rd degree heart block (n¼ 3, 25%), respectively.
DISCUSSION
This study showed a prevalence of myocarditis in aSS of
3.4%. However, the limitation of this study is inherent to its
retrospective design, and these data could have been either
underestimated due to severe undiagnosed cases7 or overesti-
mated due to recruitment bias (all centers being tertiary care
centers). There have been no reports to date in the literature
providing this specific figure for aSS, but it is comparable to
what has been reported for other inflammatory myopathies.17
Myocarditis was associated to pericarditis in half of the cases,
which is more than expected, since the frequency of isolated
pericarditis is roughly 10% in inflammatory myopathies.3
However, as confirmed by this study, pericarditis may be more
frequent in the context of aSS.6Myocarditis inaugurated aSS in 42% of the cases and was
always associated with extra-cardiac symptoms in accordance
with aSS activity, including active myositis in all cases. These
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Dieval et al
4 | www.md-journal.comdata outline the importance of seeking extra-cardiac symptoms in
cases of myocarditis to make the aSS diagnosis, which could be
confirmed by the seropositivity of anti-tRNA-synthetase
autoantibodies.
The extra-cardiac features were typical of aSS and did not
predict the occurrence of myocarditis in this context. Clinical
examination as well as first line biological and morphological
exams is not very helpful in guiding the myocarditis diagnosis.
In fact, dyspnea is common in aSS because of interstitial lung
disease or respiratory muscle involvement. Electrocardio-
graphic anomalies are nonspecific and have low sensitivity.18
Creatine kinase levels are difficult to interpret, particularly in
the context of myositis, and troponin T and I are not a sensitive
enough indicator for diagnosing myocarditis.14,15 Early echo-
cardiography is absolutely necessary when diagnosing alterna-
tive diseases,9,10 as well as when evaluating the severity of
myocarditis.9,10 However, no signs are specific to myocarditis
on echocardiography. EB should therefore be the cornerstone of
a positive diagnosis,11 but the patient’s condition rarely allows
for such an invasive procedure.
This leaves us with cardiac-MRI as the main noninvasive
tool for the diagnosis of myocarditis. When performed early,
T2-weighted images are suggestive of myocardic edema as a
spontaneous hyperintensity. Early T1-contrast after the gado-
linium injection reveals hypoperfusion zones, whereas late T1-
post-gadolinium contrasts are consistent with inflammatory
process and fibrosis.9,10,12,13 However, these delayed T1-
post-gadolinium enhancements might not distinguish myo-
carditis from chronic scarring. It is generally accepted that
the combination of these MRI features provides the highest
sensitivity and specificity.10 However, all MRI features are not
always concomitantly found and the mere presence of just one
of these indicators is associated with a good positive predictive
value (above 2/3).10 In this case series, T2-weighted was
positive only 3 times (25%). This is likely due to the fact that
the cardiac MRIs were performed rather late (up to 3 months
after first cardiac symptoms, patient 3) and/or after the patients
had begun a steroids treatment.
Since myocarditis implies severe organ involvement, it is
an important condition to diagnose in aSS. Myocarditis can
indeed lead to the development of dilated cardiomyopathy in
30% of cases.19 Moreover, in inflammatory myopathies, heart
involvement seems to be a major cause of death (about 20% of
the cases).3,4,17,20 In this series, though intensive care was
required for half of the patients, no deaths occurred. Moreover
and though 2 severe patients could have been missed, the
patients survival does not differ from that of other aSS patients.2
Three patients (30%) developed chronic left ventricle dysfunc-
tion, among which 2 presented with dilated cardiomyopathy
despite appropriate treatments. Thus, early and aggressive
therapy, including immunosuppressive drugs, seems recom-
mended.
In summary, although rare and difficult to diagnose,
myocarditis must be carefully sought out in aSS patients,
especially those with pericarditis. Starting specific treatments
early on could be important to preventing the development of
chronic dilated cardiomyopathy.
KEY MESSAGES
Prevalence of aSS-related myocarditis is 3.4%, similar to
Medicine  Volume 94, Number 26, July 2015that of other inflammatory myopathies. Although difficult in the
context of aSS, the myocarditis diagnosis is important to make:
the outcome can be severe and require specific medications.
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